Joint HTA And Pricing: How To Make Specialized Treatments like Strimvelis Affordable
Joint negotiations and outcome based deals could be key in securing access to advanced therapies like Strimvelis that are available only from specialized centers.
You may also be interested in...
NICE, the HTA body for England and Wales, has for the first time recommended a treatment – GSK’s gene therapy, Strimvelis – that is currently only available in another country. Also for the first time, NICE used a new system for determining the cost-effectiveness of highly specialized technologies such as this.
The ABPI, which represents the R&D-based pharmaceutical industry in the UK, says the proposed increase in the statutory scheme rebate sends "the worst possible signal" to global investors and boardrooms.
The German pharmaceutical industry is calling for “directional correction” to the way implementation of the EU’s Health Technology Assessment Regulation is being developed.